Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

Claudia Bruedigam, Eunice Anne Dulatre, Carol Lee, Amy H Porter, Elisa LSP Lim, Alexander Z Shi, Mark P Hodson, Florian H. Heidel, Steven W Lane

Blood (2024) 144 (Supplement 1): 52.

https://doi.org/10.1182/blood-2024-206473

Published: 2024

Journal Articles

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

Maha M Kamel, Nirmal Robinson, Monika Kutyna, Kelly Lim, Chloe Thompson-Peach, Steven W Lane, David T Yeung, Agnes S. M. Yong, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2024-204177

Published: 2024

Journal Articles

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Kelly Lim, Monika Kutyna, Winnie Kan, Angel F. Lopez, Anna Brown, Agnes S. M. Yong, Steven W Lane, Chun Yew Fong, Timothy P Hughes, David T Yeung, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2024-202682

Published: 2024

Journal Articles

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Blood (2024) 144 (Supplement 1): 476.

https://doi.org/10.1182/blood-2024-201218

Published: 2024

Journal Articles

Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Danielle N Blunt, Rosemary Harrup, Gerlinda Amor, Helen Christensen, Sarah Finlayson, Frank Lin, David M Ross, Julia Dobbins, Anna Brown, Hamish S Scott, Steven W Lane

Blood (2024) 144 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2024-207463

Published: 2024

Journal Articles

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Devendra Hiwase, David M Ross, David T Yeung, Agnes S. M. Yong, Steven W Lane, Anna Brown, Chun Yew Fong, Timothy P Hughes, John Reynolds, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2024-202867

Published: 2024

Journal Articles

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Uwe Platzbecker, Steven W Lane, Alice Garnier, Thomas Cluzeau, Odile Rauzy, Katharina S. S. Götze, Aristoteles Giagounidis, Deepak Singhal, Aicha Kopecky, Fatiha Chermat, Lionel Ades

Blood (2024) 144 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2024-194185

Published: 2024

Journal Articles

Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1 c -Flt3 ITD Acute Myeloid Leukemia

Paniz Tavakoli, Megan Bywater, Jasmin Straube, Victoria Ling, Emily Cooper, Rohit Haldar, Yashaswini Janardhanan, Leanne Cooper, Claudia Bruedigam, Carolyn S. Grove, Steven W Lane

Blood (2024) 144 (Supplement 1): 1347.

https://doi.org/10.1182/blood-2024-201250

Published: 2024

Journal Articles

Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments

Jasmin Straube, Julian Grabek, Leanne Cooper, Rohit Haldar, Caroline McNamara, David M Ross, Andrew Perkins, Megan Bywater, Steven W Lane

Blood (2024) 144 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2024-199841

Published: 2024

Journal Articles

Identifying disease-modifying potential in myelofibrosis clinical trials

David M. Ross, Steven W. Lane, Claire N. Harrison

Blood (2024) 144 (16): 1679–1688.

https://doi.org/10.1182/blood.2024024220

Published: 2024

Journal Articles

Prospective MRI and Neurocognitive Assessment of “Chemobrain” in Acute Myeloid Leukaemia: The Mineral Study

Ashleigh Scott, Ada Lo, Kate Thompson, Ying Xia, Harriet Bodimeade, Amir Fazlollahi, Cameron Curley, Steven W. Lane, Kirk Lachlan Morris, Caroline Jane McNamara, Elango S. Pillai, Nicholas Weber, Olivier Salvado, Katie L McMahon, Glen A Kennedy

Blood (2023) 142 (Supplement 1): 5850.

https://doi.org/10.1182/blood-2023-190301

Published: 2023

Journal Articles

Trp53 -Loss in Hematopoietic Stem Cells Drives the Evolutionary Process of Leukemic Transformation in a Jak2 V617F -Driven Myeloproliferative Neoplasms Mouse Model

Ranran Zhang, Yashaswini Janardhanan, Rohit Haldar, Leanne Cooper, Sebastien Jaquelin, Jasmin Straube, Megan Bywater, Steven W Lane

Blood (2023) 142 (Supplement 1): 4522.

https://doi.org/10.1182/blood-2023-188150

Published: 2023

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Monika Kutyna, Maha M Kamel, David M. Ross, Agnes S. M. Yong, Chun Yew Fong, Chloe Thompson-Peach, Steven W. Lane, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2023-179706

Published: 2023

Journal Articles

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Devendra Hiwase, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2023-179688

Published: 2023

Journal Articles

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Maha M Kamel, Monika Kutyna, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2023-188340

Published: 2023

Journal Articles

Early Generation Telomerase Deficient Mice to Investigate Clonal Hematopoiesis in Aging

Claudia Bruedigam, Amy H Porter, Jasmin Straube, Guidan Cheng, Florian H Heidel, Steven W Lane

Blood (2023) 142 (Supplement 1): 5598.

https://doi.org/10.1182/blood-2023-191246

Published: 2023

Journal Articles

Genome-wide transcription factor–binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs

Blood (2023) 142 (17): 1448–1462.

https://doi.org/10.1182/blood.2023021120

Published: 2023

Includes: Supplemental data

Journal Articles

Shelter from the cytokine storm in myelofibrosis

Steven W. Lane

Blood (2023) 141 (20): 2415–2416.

https://doi.org/10.1182/blood.2023019779

Published: 2023

Journal Articles

Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions

Blood (2022) 140 (Supplement 1): 2846–2848.

https://doi.org/10.1182/blood-2022-165620

Published: 2022

NARROW

Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1 c -Flt3 ITD Acute Myeloid Leukemia

Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments

Identifying disease-modifying potential in myelofibrosis clinical trials

Prospective MRI and Neurocognitive Assessment of “Chemobrain” in Acute Myeloid Leukaemia: The Mineral Study

Trp53 -Loss in Hematopoietic Stem Cells Drives the Evolutionary Process of Leukemic Transformation in a Jak2 V617F -Driven Myeloproliferative Neoplasms Mouse Model

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Early Generation Telomerase Deficient Mice to Investigate Clonal Hematopoiesis in Aging

Genome-wide transcription factor–binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs

Shelter from the cytokine storm in myelofibrosis

Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only